ホーム › 肺がん › オハイオ

オハイオにおける肺がんの臨床試験

オハイオ内の拠点で、肺がんに関する68件の研究が参加者を募集しています。

オハイオ内の都市

公式研究テキスト（英語）

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Cleveland Clinic Akron General, Akron
Strecker Cancer Center-Belpre, Belpre
Aultman Health Foundation, Canton
他33件

被験者募集中第3相

18歳以上 · 全性別 · 2026/10/02更新 · NCT04267848

Prospective Multiomic Analysis in Small-Cell Lung Cancer

Ohio State University Comprehensive Cancer Center, Columbus

被験者募集中観察研究

18歳以上 · 全性別 · 2026/10/02更新 · NCT07795411

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Cleveland Clinic Taussig Cancer Center, Cleveland

被験者募集中第1/2相

12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Summa Health System - Akron Campus, Akron
Cleveland Clinic Akron General, Akron
Summa Health System - Barberton Campus, Barberton
他44件

被験者募集中観察研究健康なボランティア歓迎

40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

UH Seidman Cancer Center at UH Avon Health Center, Avon
UHHS-Chagrin Highlands Medical Center, Beachwood
Strecker Cancer Center-Belpre, Belpre
他21件

被験者募集中第3相

70歳以上 · 全性別 · 2026/10/01更新 · NCT06096844

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

UH Seidman Cancer Center at UH Avon Health Center, Avon
UHHS-Chagrin Highlands Medical Center, Beachwood
Strecker Cancer Center-Belpre, Belpre
他28件

被験者募集中第3相

18歳以上 · 全性別 · 2026/10/01更新 · NCT04181060

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Aultman Health Foundation, Canton
Miami Valley Hospital South, Centerville
Ohio State University Comprehensive Cancer Center, Columbus
他4件

被験者募集中第3相

18歳以上 · 全性別 · 2026/10/01更新 · NCT06498635

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

University of Cincinnati Cancer Center, Cincinnati
The Ohio State University, Columbus

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/30更新 · NCT06765109

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

TriHealth Cancer & Blood Institute Research, Cincinnati
Taylor Cancer Research Center, Maumee

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/29更新 · NCT06881784

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]

GSK Investigational Site, Canton

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/28更新 · NCT07099898

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Aultman Hospital, Canton
Aultman Medical Group Hematology and Oncology, Canton
Oncology Hematology Care Clinical Trials, Cincinnati
他7件

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/25更新 · NCT07222566

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Dayton Physician's Network, Dayton

被験者募集中第3相

18歳〜100歳 · 全性別 · 2026/09/25更新 · NCT05920356

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

University Hospitals Seidman Cancer Center at UH Avon Health Center, Avon
University Hospitals Cleveland Medical Center, Cleveland
University Hospitals Seidman Cancer Center at UH Mentor Health Center, Mentor
他1件

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/25更新 · NCT06758401

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Cleveland Clinic, Cleveland
Local Institution - 0102, Columbus

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/09/23更新 · NCT06618287

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus

被験者募集中第2/3相

18歳以上 · 全性別 · 2026/09/23更新 · NCT07063745

A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)

GSK Investigational Site, Canton

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/09/23更新 · NCT07602855

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Research Site, Cleveland

被験者募集中第2相

18歳〜95歳 · 全性別 · 2026/09/23更新 · NCT05061550

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Gabrail Cancer Center Research, Canton
The Christ Hospital Cancer Center, Cincinnati
University of Cincinnati Medical Center, Cincinnati
他5件

被験者募集中第2/3相

18歳以上 · 全性別 · 2026/09/22更新 · NCT06712316

Pulmonary Rehabilitation in Advanced Lung Cancer Survivors

University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland

被験者募集中第2相

18歳以上 · 全性別 · 2026/09/22更新 · NCT07104630

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

University Hospitals Cleveland Medical Center, Cleveland
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C, Columbus

被験者募集中第2/3相

18歳以上 · 全性別 · 2026/09/22更新 · NCT07100080

A Study Evaluating a New Radiation Treatment Workflow (NGDS)

University Hospital Cleveland Medical Center, Cleveland

被験者募集中

21歳以上 · 全性別 · 2026/09/17更新 · NCT07824583

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
Case Western Reserve University, Cleveland
Ohio State University Comprehensive Cancer Center, Columbus
他1件

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/09/17更新 · NCT06287775

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Cleveland Clinic, Cleveland

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/09/16更新 · NCT05786924

Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

Ohio State University Comprehensive Cancer Center, Columbus

被験者募集中第1相

18歳以上 · 全性別 · 2026/09/15更新 · NCT04780568

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Ohio State University, Columbus

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/08更新 · NCT06793215

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Miami Valley Hospital South, Centerville
USO - Oncology Hematology Care, Cincinnati
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T, Columbus

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/08更新 · NCT06119581